Clinical research progression of molecular-targeted drugs and PD-1 inhibitors for advanced hepatocellular carcinoma
10.3760/cma.j.issn.0253-3766.2019.06.002
- VernacularTitle: 分子靶向药物及程序性死亡蛋白1抑制剂在晚期原发性肝癌中的临床研究进展
- Author:
Junming LAI
1
;
Shuang HU
2
;
Hong LIN
3
;
Hui LUO
3
;
Yongbiao LUO
1
Author Information
1. Radiotherapy Center, Yiwu Central Hospital, Yiwu 322000, China
2. Department of General Medicine, Yiwu Central Hospital, Yiwu 322000, China
3. Department of Oncology, the First Affiliated Hospital of Nanchang University, Nanchang 330006, China
- Publication Type:Review
- Keywords:
Liver neoplasms;
Hepatocellular carcinoma;
Molecular-targeted drugs;
Immune checkpoint inhibitors;
PD-1
- From:
Chinese Journal of Oncology
2019;41(6):406-409
- CountryChina
- Language:Chinese
-
Abstract:
Since sorafenib has been first-line molecular-targeted drug for advanced hepatocellular carcinoma (HCC), clinical studies in the last 10 years failed to confirm that a new molecular-targeted drug or immune checkpoint inhibitor was superior or non-inferior to sorafenib, or approved second-line treatment for patients with the failure of sorafenib. However, many clinical studies published in 2017 have changed people′s previous understanding. REFLECT trial showed that as the first-line treatment of advanced HCC, lenvatinib was non-inferior than sorafenib. In addition, RESORCE trial and CheckMate-040 trial confirmed respectively that regorafenib and PD-1 inhibitor nivolumab were options of second-line treatment for patients with advanced HCC after sorafenib treatment. The development of these drugs will bring a new prospect for advanced HCC patients.
